The University of Edinburgh

Haimei Chen

Peter John Sadler

Robert Edward Morris

Duncan Jodrell

Ruthenium (II) compounds of the formula:wherein: Ris &#x2014;COCH; R, R, R, Rand Rindependently represent H, alkyl, cylcoalkyl, &#x2014;COR', aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R&#x2032; represents alkyl, cylcoalkyl, aryl or alkaryl; X is halo, HO, (R&#x2032;)(R&#x2033;)SO, R&#x2032;COor (R&#x2032;)(R&#x2033;)C&#x2550;O, where R&#x2033; represents alkyl, cylcoalkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C&#x2032; is Cto Calkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently R&#x2014;CN, where R&#x2033; represents alkyl or cycloalkyl; or B is halo and A is 4-substitued pyridine; or p is 0, A is NRRand B is NRRwherein R, R, Rand Rindependently represent H, or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NRand B is NRR, wherein R, Rand Rare as previously defined, and A and B are linked by an alkylene chain, optionally substituted are described.

Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer

Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein Rand Rtogether with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group

Ruthenium (II) compounds for use in the therapy of cancer

Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R , R , R , R , R and R independently represents H, alkyl, &mdash;CO R&prime;, aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R&prime; represent alkyl, aryl or alkaryl; X is halo, H O, (R&prime;)(R&Prime;)SO, R&prime;CO &mdash; or (R&prime;)(R&Prime;)C&boxH;O, where R&Prime; represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C&prime; is C to C alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR R and B is NR R , wherein R , R , R and R independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain, or p is 1, A is NR and B is NR R , wherein R , R and R are as previously defined, and A and B are linked by an alkylene chain, optionally substituted.

Growing community of inventors

Edinburgh, United Kingdom

Haimei Chen